The toxicokinetics and toxicity profile of belatacept (LEA29Y), which blocks the CD28 costimulation pathway to prevent T-cell activation, were evaluated in cynomolgus monkeys. In the current study, 30 monkeys (five monkeys per sex per group) received an intravenous dose of belatacept (10, 22, or 50 mg/kg) once weekly for 6 months. An additional five monkeys per sex received saline intravenously and served as controls. Systemic exposure to belatacept was dose proportional and similar for both sexes. Multiple dosing resulted in moderate belatacept accumulation (1.6-to 1.9-fold). Belatacept was clinically well tolerated in monkeys, with no drug-related laboratory parameter changes or target organ toxicity observed, including a lack of nephrotoxicity. Drug-related changes, which were reversible and related to the pharmacology, included dose-dependent minimal/mild reduction in the size and number of lymphoid germinal centers of the spleen and lymph nodes and minimal reductions in serum IgG levels. No antibodies specific for belatacept were detected during the treatment period. There were no changes in peripheral blood or splenic lymphocyte subpopulations or indications of autoimmunelike inflammation, infection, or malignancy, including preneoplastic changes. Functional recovery of the immune system was noted at all doses by a robust antibody response to keyhole limpet hemocyanin following immunization 2 months after the last belatacept dose was administered. Thus, belatacept was well tolerated in monkeys treated for 6 months at weekly doses up to 50 mg/kg, which represented a 20-fold increase above exposures achieved by the approved maintenance dose in kidney transplant recipients. These findings support the belatacept safety profile and demonstrate that belatacept does not result in adverse renal effects.
Belatacept (LEA29Y) is the first biologic agent approved in the United States and Europe for primary maintenance immunosuppression for solid organ transplantation. This agent is a selective costimulation blocker that combines a modified extracellular portion of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with the constant region fragment of human IgG 1 (Larsen et al., 2005) . Full activation of T cells requires two signals: an antigen recognition signal, relayed through the T-cell receptor, and a costimulatory signal, which is activated via binding of CD28 on T cells to CD80 and CD86 present on the surface of antigen-presenting cells. CD80 and CD86 also transmit an inhibitory signal to activated T cells upon binding to CTLA-4, which is transiently upregulated following T-cell activation, attenuating the T-cell response.
Belatacept is a human fusion protein, in which two amino acid substitutions were made in the ligand-binding region of CTLA-4. As a result of these modifications, belatacept binds CD80 and CD86 more avidly than abatacept, the parent CTLA-4 Ig molecule from which it is derived. By binding CD80 and CD86 and preventing its ligation of CD28 on T cells, belatacept prevents full T-cell activation by the costimulatory signal. Belatacept safely and specifically controls the recipient's T-cell response to a donor allograft, thereby achieving normal function and long-term survival of a transplanted organ. In contrast, current immunosuppressive agents used for primary maintenance immunosuppression, such as cyclosporine, target ubiquitous cell-signaling proteins, resulting in nonimmune, offtarget toxicities, including nephrotoxicities that reduce the function, structural integrity, and long-term survival of the kidney. Belatacept has been developed to avoid these off-target toxicities by specifically blocking the costimulatory signal.
Belatacept is pharmacologically active in nonhuman primates as demonstrated by the ability of belatacept to suppress T-celldependent antibody responses in cynomolgus monkeys following single intravenous dose (> 99% inhibition at dose of 0.5 mg/ kg) and to significantly prolong renal allograft survival in rhesus monkeys (Larsen et al., 2005) . Belatacept is also well tolerated in cynomolgus monkeys when administered by single intravenous doses up to 90 mg/kg (Bristol-Myers Squibb, 1998) .
To evaluate the chronic toxicity profile of belatacept, the current study investigated the repeat-dose toxicity and toxicokinetic profile in cynomolgus monkeys administered belatacept as an intravenous dose once weekly for 6 months. In addition to standard toxicology parameters to assess the immune system (clinical observations and clinical/anatomical pathology), the following special evaluations were conducted: levels of serum/plasma histamine, C3a complement, tumor necrosis factor (TNF-a), and interleukin (IL)-6 following dosing and peripheral blood and splenic lymphocyte phenotyping, serum immunoglobulin (Ig) levels, and immunogenicity at various time points throughout the study. The ability of monkeys to mount a robust T-cell-dependent antibody response to keyhole limpet hemocyanin (KLH) following immunization after an 8-week dose-free period was also evaluated to demonstrate the reversibility of the immunomodulatory activity of belatacept.
Belatacept is currently approved for immunosuppression in kidney transplant recipients. The data presented here include pivotal chronic toxicology data that were required by health authorities to support long-term clinical trials and for the approval of belatacept in this indication.
MATERIALS AND METHODS
Materials. Belatacept, manufactured using recombinant DNA technology, was expressed genetically in and produced by a Chinese hamster ovary cell line. The final belatacept product used was lyophilized in vials with the following components: 125 mg belatacept, 250 mg sucrose, 17.25 mg sodium phosphate monobasic monohydrate, 2.9 mg sodium chloride, and 1 N sodium hydroxide/1 N hydrochloric acid solution sufficient to adjust pH to 7.5. The vials were refrigerated at 2-8°C prior to reconstitution with 2.3 ml of water for injection and diluted for dosing in 0.9% sodium chloride for injection, prior to use. The immunogen KLH was purchased from Pacific Bio-Marine Laboratories, Venice, CA. Prior to use, the KLH was dialyzed against PBS and centrifuged. The supernatant fraction was removed, sedimented, and the pellet resuspended in PBS to a concentration of 10 mg/ml and stored at 2-8°C. All dosing solutions were sterile filtered using a Sterile Acrodisc Syringe Filter (Catalog no. 4192; Gelman Sciences, Inc., Ann Arbor, MI).
Study design. Forty experimentally naive cynomolgus monkeys (Macaca fascularis) between 2.4 and 4.5 kg and 1.5-3.5 years of age were obtained from Charles River BRF, Inc., Houston, TX, for the study. All monkeys underwent a comprehensive health evaluation and screening, which included demonstration of seronegativity for simian retroviruses (simian retrovirus [SRV] , simian immunodeficiency virus [SIV] , and simian T-cell leukemia virus-1 [STLV-1]). Male and female monkeys were assigned to one of four treatment groups by a stratified randomization scheme designed to achieve similar group mean body weights and each group contained five monkeys per sex. Monkeys were acclimated to nonhuman primate chairs prior to study initiation and were not sedated for dose administration.
Monkeys were administered a single intravenous bolus dose (0.1 ml/s) of belatacept at 0 (saline control), 10, 22, or 50 mg/kg once per week for 6 months via the saphenous vein at a fixed concentration of 25 mg/ml. The once weekly schedule of belatacept was based on available pharmacokinetic data and was intended to be as frequent as, or more frequent than, the clinical dose schedule and to provide exposure multiples similar to or higher than the highest intended clinical exposure. Furthermore, the doses exceeded those shown to suppress T-cell-dependent antibody responses and prevent rejection in an allogeneic renal transplant model in monkeys (Larsen et al., 2005) . The first three monkeys per sex in each group were necropsied following 6 months of treatment with belatacept. The remaining two monkeys in each group were retained for an additional 3-month dose-free observation period. Approximately 2 months into the 3-month dose-free period, these monkeys were immunized with an intramuscular injection of KLH at a dose of 10 mg per animal to evaluate for reversibility of the pharmacologic activity of belatacept and to evaluate the functional activity of the immune system. Monkeys were then necropsied at the end of the 3-month dose-free period.
Toxicokinetic measurements and analyses. Whole blood samples were collected from each unanesthetized monkey for the evaluation of systemic exposure of belatacept at the following time points: predose, 3 min postdose, and 2, 6, 24, 72, 120, and 168 h postdose after dosing on days 1, 78, and 176. Additional samples were collected from the remaining recovery monkeys 14, 28, and 42 days after the last dose for determination of the terminal half-life (t 1/2 ). Serum samples were analyzed for belatacept by a validated ELISA method that had a lower limit of quantitation of 3 ng/ml. Serum concentrations at each blood sampling time were averaged for the monkeys bled at that time point for each dose level and gender. Concentrations below the lower limit of quantitation were treated as zero for calculating the mean concentration and associated SD. The maximum concentration in serum was recorded directly from experimental analyses. The area under the serum concentration versus time curve in a dosing interval (AUC tau , where tau ¼ 168 h) was calculated by the trapezoidal rule on days 1, 78, and 176.
Clinical/general observations. Monkeys were observed daily for clinical signs or behavioral changes. Body weights were recorded once weekly and prior to scheduled necropsies. Food consumption was recorded daily beginning 5-6 days before study initiation. Body temperature was measured prior to dosing and 1 h postdose during weeks 4, 8, 16, 25 , and at the end of the 3-month dose-free period. Physical, including respiratory and neurologic function, and ophthalmologic examinations were conducted under light sedation prior to study initiation and prior to scheduled necropsy. Electrocardiographic evaluations were conducted under light sedation prior to study initiation, at 4 h postdose following 3 months of dosing, and prior to scheduled necropsy.
Immunologic assessments. Serum Ig assessments were performed prior to study initiation, predose during weeks 3, 7, 14, and 24 and in recovery monkeys during week 37. All monkeys receiving belatacept were evaluated for formation of belatacept-specific antibodies (immunogenicity) on serum samples collected prestudy and during weeks 3, 7, 12, 15, 20, 24, and 38 . Recovery monkeys were assessed for KLH-specific antibodies on serum samples collected prior to immunization (week 35) and weekly for 3 weeks following immunization. Histamine and complement C3a were evaluated from plasma samples collected prior to study initiation, predose, and 3 and 30 min postdose during weeks 4, 8, and 25. TNF-a and IL-6 were assessed from serum samples collected predose and 1, 2, and 4 h postdose during weeks 4, 8, and 25.
Serum levels of IgM, IgG, and IgA were assessed using ELISAs, which relied on the cross-reactivity of monkey Igs with commercially available antihuman Ig heavy and/or light chain antibodies. Standard curves were generated using calibrated human serum, and thus absolute values must be interpreted with caution. Formation of antibodies directed against belatacept, and KLH were also evaluated by ELISA. Histamine, C3a, TNF-a, and IL-6 levels were all measured by ELISA, using commercially available kits obtained from Beckman Coulter Immunotech Division (Miami, FL), Quidel (San Diego, CA), Pharmingen (San Diego, CA), and R&D Systems (Minneapolis, MN), respectively. These kits cross-react with the corresponding proteins in monkeys. However, standard curves were generated using calibrated human protein, and thus absolute values must be interpreted with caution.
The following were analyzed by flow cytometric analyses: whole blood samples for the evaluation of peripheral blood lymphocyte subpopulations collected in ethylenediamine tetraacetic acid tubes prior to study initiation, predose during weeks 3, 7, 14, and 24, and in recovery monkeys during week 37; and single-cell suspensions of splenocytes prepared from one-third of the spleen collected at scheduled necropsies (which were mashed and the cells suspended in buffered saline) were evaluated for lymphocyte subpopulations. Flow cytometric analysis was performed on the Coulter EPICS XL-MCL Flow Cytometer (Coulter Corporation, Miami, FL). Flow cytometry was used to determine percentages of pan-T-cells (CD2), T-helper cells (CD4), T-cytotoxic cells (CD8), and B cells (CD20) on peripheral blood and splenic lymphocytes.
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Staining was performed using commercially available fluorochrome-conjugated antibodies directed against human CD2, CD4, CD8 (obtained from Exalpha Corporation, Boston, MA), and CD20 (obtained from Becton, Dickinson and Company, San Jose, CA), which have been shown to cross-react with surface markers on cynomolgus monkey lymphocytes. A commercial antibody that cross-reacted with cynomolgus monkeys CD3 was not readily available in 1999 when this study was conducted. Absolute numbers of peripheral blood lymphocytes expressing each marker were calculated as the product of the total lymphocyte count and the percentage of lymphocytes expressing a given marker. Normal ranges of peripheral blood lymphocyte subpopulations were determined by estimating the central 95% of current historical control values of combined male and female monkeys as determined by the Bristol-Myers Squibb immunotoxicology laboratory with the high and low 2.5% of the values eliminated.
Clinical pathology. Blood samples were collected for clinical pathologic evaluations (hematology, serum chemistry, and coagulation) from the femoral vein from fasted anesthetized monkeys prestudy and during weeks 3, 7, 15, and 24, and in recovery monkeys prior to necropsy. Urine was collected prestudy and prior to scheduled necropsies for urinalysis.
Standard hematology evaluation of whole blood collected into tubes containing ethylenediamine tetraacetic acid anticoagulant included red blood cell count, white blood cells (total and differential), hemoglobin concentration, hematocrit, reticulocyte count, mean cell hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, platelet count, and blood cell morphology. Samples were analyzed on an Abbott Cell-Dyn 3500 multiparameter automated hematology analyzer (Abbott Labs, Pomezia, Italy). In addition, total lymphocyte counts were periodically determined for use in combination with flow cytometry data.
For serum chemistry samples, sera were analyzed on a Beckman Synchron CX7 automated chemistry analyzer (Beckman-Coulter Instruments, Palo Alto, CA). The following parameters were analyzed: sodium, potassium, chloride, carbon dioxide, total bilirubin, alkaline phosphatase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, calcium, phosphorus, urea nitrogen, creatinine, total protein, albumin, globulin, albumin/globulin ratio, glucose, cholesterol, and triglycerides.
For assessment of coagulation parameters, plasma from whole blood collected into tubes containing sodium citrate anticoagulant was analyzed for activated partial thromboplastin time, prothrombin time, and fibrinogen on a Sigma AMAX CS 190 (Sigma Diagnostics, St Louis, MO).
Urinalysis was performed on samples obtained from the bladder at necropsy. The following parameters were determined: color/character (observation); specific gravity (refractometer); pH, leukocyte esterase, nitrite, urobilinogen, protein, glucose, ketones, bilirubin, and occult blood (dipstick); and casts, leukocytes, erythrocytes, epithelial cells, mucus, crystals, bacteria, yeast, and amorphous sediment (microscopic evaluation of sediment).
Anatomic pathology. Complete gross pathologic examinations, including recordings of selected organ weights and necropsy findings, were performed on all monkeys. Absolute organ weights and relative organ to body and organ to brain weight ratios were evaluated for treatment effects. The following tissues were collected at necropsy and examined microscopically: adrenal gland, aorta, bone, bone marrow, brain, cecum, cervix, colon, duodenum, epididymis, esophagus, eye, gallbladder, heart, ileum, iliac node, jejunum, kidney, lung, mammary gland, mandibular node, mesenteric node, ovary, pancreas, parathyroid gland, peripheral nerve, pituitary gland, prostate, seminal vesicle, skeletal muscle, skin, spinal cord, spleen, testis, thymus, thyroid gland, tongue, trachea, urinary bladder, uterus, vagina, and injection sites. Tissues were collected, preserved, and examined histologically by a pathologist, and selected tissues were peer-reviewed by a second pathologist. Drug-related and spontaneous findings were recorded for each study animal.
Statistical methods. Pharmacokinetic analyses of the concentration versus time data were performed by the PKMENU application using the Statistical Analysis System (SAS, version 6.12) software package. Data on body weights, food consumption, clinical pathology, and organ weights were analyzed using Dunnett's test. Clinical immunology and anatomic pathology data were analyzed using nonstatistical methods.
RESULTS

Toxicokinetic Analyses
A summary of the toxicokinetic data for belatacept in cynomolgus monkeys is presented in Table 1 . Systemic exposure to belatacept was dose proportional, with overall exposures similar for male and female monkeys. Steady state was attained by day 78 following repeated weekly dosing, consistent with the t 1/2 . Repeat dosing resulted in a 1.6-to 1.9-fold accumulation of belatacept. Figure 1 shows the mean serum belatacept concentration-time profile following administration of the last dose on day 176. Mean belatacept t 1/2 at day 176 ranged from 5.6 to 9.0 days. After a 2-month treatmentfree period, blood levels of belatacept were either below the limits of detection or were significantly less than those measured after administration of the last dose on day 176. None of the animals developed detectable antibelatacept antibodies during the dosing period.
General Observations
Belatacept was well tolerated; no drug-related changes in clinical signs, body weight, or food consumption were noted during the study. No drug-related changes were observed in physical, ophthalmologic, neurologic, or electrocardiographic examinations or in heart rate, body temperature, or respiratory rate. Most findings were considered typical of background observations in monkeys undergoing study procedures and were distributed similarly across all treatment groups including controls. On day 1 of the study, one low-dose male monkey exhibited behavior consisting of vigorous scratching of the inguinal and caudal abdominal area causing erythema and excoriation of the skin observed 6 h postdose. Blood samples were collected for histamine analysis 0, 3, and 30 min following the second dose on day 8 to determine if the scratching was histamine mediated. Histamine levels were not increased at any time point. The behavior was not considered drug related as it only occurred when the monkey was chaired, and the findings resolved when time in the chair was minimized. One low-dose female monkey was given an unscheduled physical examination due to an extended period of diarrhea. A stool sample was cultured for bacteria and examined for parasites. No pathogenic organisms were identified. On day 80, the animal was treated with 66 mg of bismuth subsalicylate. The diarrhea resolved by day 82.
Immunologic Assessments
No drug-related changes were noted in the absolute numbers or percentages of peripheral blood lymphocytes expressing CD2, CD4, CD8, or CD20 either within or between study groups (Supplementary table 1a and b) . In the data, variations over time in peripheral blood absolute lymphocyte counts were observed among and across all treatment groups, including controls, and represent the wide range of normal lymphocyte counts for monkeys. The wide range for normal lymphocyte counts in monkeys is supported by the wide range and variation in lymphocyte counts in the pretreatment period of all monkeys. When lymphocyte counts for each treatment group at each time point were compared with controls and with pretreatment values for respective groups, no significant treatment or length of treatment differences were observed in lymphocyte counts of male or female animals. Moreover, no drug-related differences in the percentages of splenic lymphocytes were observed between control-and belatacept-treated animals, although a decrease in the lymphoid germinal centers was observed histologically (Table 2) . Mean ± SD of all animals in each group necropsied in week 27(n ¼ 6).
b Mean ± SD of remaining animals in each group necropsied in week 38 (n ¼ 4).
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Serum Ig analyses, presented in Table 3 , showed minimal reversible reductions in serum IgG levels in belatacept-treated monkeys. Compared with mean vehicle-control IgG levels, mean IgG levels in males decreased by 13, 23, and 34%, with belatacept at 10, 22, and 50 mg/kg, respectively, by the end of treatment. Mean IgG levels in females decreased by 22, 34, and 31%, respectively. IgG levels remained within the normal limits for monkeys observed in the control groups in other studies and were not considered clinically significant. In general, serum IgG levels were restored by the end of the dosefree observation period. No drug-related changes in serum IgM or IgA levels were noted. Although IgM and IgA levels did fluctuate, these changes were seen in control and treated groups throughout the study, including both pre and postdose periods. A decrease observed in IgM and IgA in the 50 mg/kg group at week 38 was a reflection of the decreased number of monkeys in the recovery period as individual values did not differ from individual prestudy values.
No antibelatacept antibodies were detected during the 6-month dosing period. However, minimal belatacept-specific antibody responses were detected in all dose groups at week 38, after the 3-month dose-free observation period. Antibelatacept antibodies were detected in four of six males and three of six females with titers of 90-270, as compared with prestudy titers of 10-30. These late-appearing antidrug antibody responses did not affect exposures to belatacept during the treatment period.
Analysis of immune mediators, which could have potential downstream changes that might have secondary effects on hemodynamic and/or cardiovascular responses, revealed no apparent drug-related changes in levels of plasma or serum histamine, complement C3a, IL-6, or TNF-a following dosing with belatacept. Sporadic postdose IL-6 elevations were observed in all animals, including controls, and were thought to be due to handling-related stress described previously (Takaki et al., 1994; Tsagarakis and Grossman, 1994) .
During the recovery period, functional activity of the immune system was demonstrated by a robust T-cell-dependent antibody response to KLH in all monkeys, demonstrating reversibility of immunosuppression and the lack of an adverse effect on the immune system following long-term treatment with belatacept. KLH is a T-cell-dependent antigen that requires the interaction of B cells, T cells, and macrophages for the animal to develop a humoral KLH-specific antibody response. Treatment with belatacept has been previously demonstrated to significantly suppress the humoral immune response to T-cell-dependent antigens at doses well below those utilized in this study (Larson et al., 2005) . The KLH immunization was thus performed to demonstrate the reversibility of belatacept's effect on the immune function following 6 months of treatment and after a 2-month dose-free recovery period, once belatacept had dropped below biologically active levels. Anti-KLH antibodies were detected in animals in all dose groups, as shown in Figure 2 . However, lower titers were observed in two of the four high-dose monkeys relative to controls and other treated monkeys, suggesting that these animals may not have fully recovered at the time of immunization, consistent with the long half-life of the drug and greater time needed to clear the drug to below active levels at the highest dose level.
Clinical and Anatomic Pathology
There were no hematologic, serum chemistry (Supplementary table 2a and 2b) , coagulation, or urinalysis abnormalities that were considered to be related to belatacept exposure (data not shown). All monkeys survived to scheduled necropsies, no (Supplementary table 3) . After 6 months of treatment, the only drug-related histopathologic changes associated with belatacept were minimal to moderate decreases in the size and numbers of lymphoid germinal centers, the size of periarteriolar lymphocyte sheaths of the spleen, and the size of germinal centers of mesenteric/mandibular lymph nodes; however, a corresponding decrease in circulation lymphocyte counts was not observed. Affected germinal centers were either absent or contained reduced numbers of immature lymphocytes and centroblasts, which are present in the center of the active germinal centers. Decreased germinal center activity was consistent with the pharmacology of the drug (Ferguson et al., 1996) and was reversible following a 3-month dose-free observation period. Germinal center depletion was observed in animals at all doses, and the effect appeared to be dose-dependent (Fig. 3) .
No other drug-related histopathologic changes were noted. Importantly, there was no evidence of microscopic changes in the renal glomeruli to suggest an autoimmune or immunologic response to the drug or other evidence of nephrotoxicity, and no treatment-related changes were present in blood urea nitrogen and serum creatinine (Supplementary Tables 2a and  2b ). There was also no evidence of lymphomas or other solid tumors, or hyperplastic, preneoplastic morphologic changes, such as lymphoid hyperplasias, observed in monkeys following a 6-month treatment period with belatacept or a 3-month dosefree recovery period.
Two male monkeys (1 low-dose and 1 high-dose monkey) had parasites in the large intestine, which were not associated with enteric histopathology. Minimal to mild acanthosis and inflammation were observed at various skin sites in some female monkeys, which were reduced following the 3-month drug-free observation period. However, it was unclear whether these minor findings were incidental or related to immunosuppressive effects of belatacept. Aside from the aforementioned parasites, which can be common in monkeys, there was no evidence of infections in belatacept-treated animals.
DISCUSSION
Overall, belatacept was clinically well tolerated in monkeys when given intravenously at doses up to 50 mg/kg once a week for 6 months with no target organ toxicity. Toxicokinetic analyses revealed that systemic exposure to belatacept was dose proportional, with no gender differences. Systemic exposures (AUCs) achieved in this study for the 50 mg/kg dose, the no-observable adverse-effect level, were 6, 13, and 21 times greater than those achieved by kidney transplant recipients dosed with the approved belatacept dosing regimen during the first and fourth months posttransplant and maintenance phase, respectively (Shen et al., 2010) .
Immunodeficiency is a common side effect of immunosuppressants, resulting in increased susceptibility to serious infections and cancer. As a selective immunomodulatory agent, the effects of belatacept on the immune system were thoroughly evaluated in this study. In addition to standard toxicology endpoints (clinical observations and clinical and anatomical pathology), a number of special endpoints were included to evaluate the effect of belatacept on the immune system following chronic treatment. Overall, the immunologic findings in monkeys treated for up to 6 months with belatacept were characterized as reversible pharmacologic effects that consisted of (1) minimal decreases in serum IgG (no effect on IgM or IgA) and (2) minimal to moderate decreases in the number and diameter of lymphoid germinal centers in the spleen and/or lymph nodes, reflective of decreased germinal center activity, at all doses. There were no effects on the absolute numbers of peripheral blood lymphocytes or percentage of splenic lymphocyte subpopulations, indicating that chronic treatment did not deplete lymphocytes. Functional recovery of the immune system was also demonstrated in a subset of monkeys observed for a 3-month dose-free period after the 6-month treatment period. Following KLH immunization 2 months after the last belatacept dose, robust anti-KLH antibodies were detected in all of these monkeys at all dose levels.
Clinical manifestations resulting from primary infections or the reactivation of persistent latent infections is a potential concern with any prolonged immunosuppression (Allen and Preiksaitis, 2009; Everly et al., 2007; Morales et al., 1997) . Decreases in serum IgG levels and/or germinal center activity, including suppression of T-cell-dependent antibody responses during drug treatment, which has been demonstrated previously (Larsen et al., 2005) , did not result in any clinical or histological manifestations associated with bacterial, fungal, or 
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HAGGERTY AND PROCTOR viral infection in this study despite exposures that exceed maximal pharmacological activity for up to 6 months. Although it was determined that the monkeys were negative for simian retroviruses (SRV, SIV, and HTLV-1) prior to being placed on study, the viral status to other viruses in the 6-month belatacept monkey study was not determined. However, these monkeys likely harbored lymphocryptovirus (LCV), cytomegalovirus (CMV), and SV40, as these viruses are prevalent in macaque monkey colonies with seroprevalence rates > 90-95% in juvenile and young adult macaques. Infections are asymptomatic in healthy macaques, and these viruses spread rapidly within a colony. In monkeys under the condition of prolonged immunosuppression, these viruses may become active and result in clinical manifestations. LCV infection has been associated with lymphoproliferative disease and development of B-cell lymphomas. LCV is homologous to the human oncogenic virus Epstein-Barr virus. CMV infection can result in disseminated lesions in a number of tissues, including the brain, lymph nodes, spleen, liver, and kidney. SV40 has been associated with neurologic disease and can be detected in brain, lung, kidney, and lymphoid tissues. Despite long-term treatment at clearly immunosuppressive doses, no clinical signs or lesions associated with these viruses developed in monkeys receiving belatacept for 6 months. Lymphoid tissues were evaluated by pathologists with knowledge of the subtle lymphoid lesions (plasmacytoid hyperplasia and polymorphic lymphoid hyperplasia) associated with LCV and precursors to the development of lymphomas. No evidence of lymphomas, other solid tumors, or preneoplastic morphologic changes, including lymphoid hyperplasia, were detected.
CD28 is expressed in humans and monkeys on most CD4þ T cells and, to a lesser extent, CD8þ T cells. However, data suggest that there may be some differences in the expression of CD28 in certain subpopulations. Specifically, human CD4þ effector memory T cells appear to maintain CD28 expression, whereas macaque CD4þ T effector memory T cells do not (Pitcher et al., 2002) . It has been suggested by Eastwood et al. (2010) that this difference may have been the reason that the cynomolgus monkeys did not predict the in vivo cytokine storm observed in humans with an anti-CD28 superagonist antibody (TGN1412) designed to stimulate CD28 (Eastwood et al., 2010) . Effector memory T cells play an important role in the defense against chronic viral pathogens. Based on the complexity of T-cell-receptor biology, the importance of CD28 expression on CD4þ effector memory T cells in the control of human viral pathogens, and how the lack of this expression on macaque effector memory cells translates functionally across species, is unclear at this time. Inhibition of CD28 costimulation could theoretically lead to autoimmune-like inflammation through several different pathways, including an indirect effect on T-regulatory cells or through the development of anti-CTLA-4 antibodies that block the endogenous CTLA-4 receptor. CD28 signaling in T-regulatory cells has been shown to promote FoxP3þ T-regulatory cell generation from developing thymocytes (Tai et al., 2005) and to maintain peripheral T-regulatory cell homeostasis and expansion in rodents (Salomon et al., 2000; Tang et al., 2003) . Because T-regulatory cells are believed to play an important role in regulating immune responses associated with self-regulation and tolerance, a decrease in the number of T-regulatory cells, which would result in a decrement in functionality, could potentially lead to autoimmune-like inflammation. However, inhibition of CD28 costimulation by abatacept, which is currently marketed for the treatment of rheumatoid arthritis, has been shown to prevent and/or reduce autoimmunity in many animal models and humans (Genovese et al., 2005; Khoury et al., 1995; Kremer et al., 2003; Lenschow et al., 1995) . Furthermore, the potential for antibelatacept antibodies reactive to the CTLA-4 portion of the molecule that could cross-react with endogenous CTLA-4 and interfere with normal T-cell homeostasis leading to autoimmunity is a theoretical concern, based on findings with therapeutic monoclonal anti-CTLA-4 antibodies (Brunner et al., 1999; Greenwald et al., 2002; Krummel and Allison, 1996; Walunas et al., 1996) . However, based on a comprehensive evaluation of clinical and anatomical pathology of all organs, no changes observed in any of the parameters or tissues evaluated were suggestive of autoimmune-like inflammation in monkeys chronically administered belatacept. In addition, the frequency of T-regulatory cells in patients treated with belatacept along with other immunomodulatory agents in a renal transplant study were similar to those in patients treated with calcineurin inhibitors (CNIs) (Bluestone et al., 2008; Chavez et al., 2007) , and there have been few reports of autoimmune events in the clinic. Nonetheless, this remains a potential risk, and autoimmune events will be tracked postmarketing.
Because belatacept is a parenterally administered therapeutic protein, it could potentially elicit an antibody response to itself. Although immunogenicity studies in primates are not predictive of results in humans, the presence of belatacept-specific antibodies, if they existed, might have a negative influence on the efficacy and safety profile of belatacept via antibodymediated clearance, neutralization of binding activity, and general immune-mediated toxicities, such as systemic infusion reactions, local injection reactions, and hypersensitivity reactions. Antibelatacept antibodies were not detected during the treatment period, a finding consistent with either the immunosuppressive activity of belatacept or the interference of belatacept with the immunogenicity assay employed in this trial. However, belatacept-specific antibodies were detected in the monkeys after belatacept serum levels had dropped below immunosuppressive levels, 12 weeks after the completion of treatment. This immunogenicity did not affect exposure during the treatment period.
CNIs are a cornerstone of immunosuppressive therapy, with the vast majority of kidney transplant recipients receiving posttransplantation CNI-based immunosuppression (Andreoni et al., 2007) . Two pivotal phase III trials, BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) and BENEFIT-EXT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial-EXTended criteria donors) (Durrbach et al., 2010) , demonstrated similar patient/graft survival, better preservation of renal function, and an improved cardiovascular/metabolic risk profile for belatacept compared with cyclosporine. Increased CNI dosage and serum concentration levels have been directly associated with decreased renal function, including increases in blood urea nitrogen and serum creatinine, proteinuria, serum electrolyte changes (sodium, potassium, calcium, and phosphorus), and erythrocytes or leukocytes in the urine (Klintmalm and Gonwa, 1995; Olyaei et al., 1999; Rezzani, 2004; Shihab et al., 1997; Stillman et al., 1995) . These effects were not seen in this study, which tested belatacept at doses of up to 6 times the human equivalent at the initial (highest clinical exposure) phase in human trials . CNIs have also been associated with histopathologic changes in nonhuman kidneys (Bing et al., 2006; Daar et al., 1987; Jain et al., 2000; Khanna and Pieper, 2007; Kinugasa et al., 2008; Lloberas et al., 2008; Nielsen et al., 2003; Ninova et al., 2004; Treska et al., 2004; Wijkstrom et al., 2005) . Importantly, in this study, there was no evidence of the structural changes that might be associated with nephrotoxicity in any of the belatacept-treated monkeys. This is in stark contrast with the adverse impact on histopathologic and renal function that CNIs have in both animal models and humans (Meier-Kriesche et al., 2004; Nankivell et al., 2004) .
In summary, this study demonstrates a lack of toxicity following chronic treatment with belatacept in monkeys at doses that produce maximal pharmacologic activity as demonstrated by suppression of T-cell-dependent antibody responses. Importantly, no evidence of nephrotoxicity, autoimmunity, infections, or malignancies associated with belatacept was observed. This study supports the potential benefits associated with the use of belatacept in humans with the approved dose recommended for renal transplant recipients and further supports phase III clinical trial results that show the absence of nephrotoxicity and preservation of renal function in belatacept patients over 3 years posttransplant (Larsen et al., 2010) .
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